title: Folate dependence of hyperhomocysteinemia and vascular dysfunction in cystathionine beta-synthase-deficient mice.
abstract: Hyperhomocysteinemia is a risk factor for stroke, myocardial infarction, and venous thrombosis. Moderate hyperhomocysteinemia is associated with impaired endothelial function, but the mechanisms responsible for endothelial dysfunction in hyperhomocysteinemia are poorly understood. We have used genetic and dietary approaches to produce hyperhomocysteinemia in mice. Heterozygous cystathionine beta-synthase-deficient mice (CBS +/-), which have a selective defect in homocysteine transsulfuration, and wild-type (CBS +/+) littermates were fed either a control diet or a diet that is relatively deficient in folic acid for 6 wk. Plasma total homocysteine was 5.3 +/- 0.7 microM in CBS +/+ mice and 6.4 +/- 0.6 microM in CBS +/- mice (P = 0.3) given the control diet. Plasma total homocysteine was 11.6 +/- 4.5 microM in CBS +/+ mice and 25.1 +/- 3.2 microM in CBS +/- mice (P = 0.004) given a low-folate diet. In mice fed the control diet, relaxation of aortic rings in response to the endothelium-dependent vasodilator acetylcholine did not differ significantly between CBS +/+ mice and CBS +/- mice. In contrast, in mice fed a low-folate diet, maximal relaxation to acetylcholine was markedly impaired in CBS +/- mice (58 +/- 9%) compared with CBS +/+ mice (84 +/- 4%) (P = 0.01). No differences in relaxation to the endothelium-independent vasodilator sodium nitroprusside were observed among the four groups of mice. These data indicate that CBS-deficient mice are predisposed to hyperhomocysteinemia during dietary folate deficiency, and moderate hyperhomocysteinemia is associated with marked impairment of endothelial function in mice.
authors.affiliation: Veterans Affairs Medical Center, Iowa City 52246, USA. steven-lentz@uiowa.edu
authors.forename: S R
authors.initials: SR
authors.lastname: Lentz
authors.forename: R A
authors.initials: RA
authors.lastname: Erger
authors.forename: S
authors.initials: S
authors.lastname: Dayal
authors.forename: N
authors.initials: N
authors.lastname: Maeda
authors.forename: M R
authors.initials: MR
authors.lastname: Malinow
authors.forename: D D
authors.initials: DD
authors.lastname: Heistad
authors.forename: F M
authors.initials: FM
authors.lastname: Faraci
mesh_terms: D000818:Animals; D001011:Aorta / Q000187:drug effects / Q000378:metabolism; D003541:Cystathionine beta-Synthase / Q000172:deficiency* / Q000235:genetics; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000378:metabolism*; D005492:Folic Acid / Q000378:metabolism*; D005526:Food, Formulated; D006579:Heterozygote; D006710:Homocysteine / Q000097:blood; D020138:Hyperhomocysteinemia / Q000097:blood* / Q000235:genetics; D066298:In Vitro Techniques; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism; D018180:Thrombomodulin / Q000378:metabolism; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D018180:Thrombomodulin; D014665:Vasodilator Agents; D006710:Homocysteine; D005492:Folic Acid; D003541:Cystathionine beta-Synthase